Lisaftoclax

Diffuse Large B-Cell Lymphoma

Ruijin HospitalSmall moleculePhase 2Active

B

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 81/ 100

Competitive context

252 Active assets in the Diffuse Large B-Cell Lymphoma cohort.

Asset / Sponsor	Phase	Rating
VINCRISTINE SULFATE National Cancer Institute (NCI)	Phase 2/3	A
MELPHALAN Ruijin Hospital	Phase 4	BBB
Axicabtagene Ciloleucel Ruijin Hospital	Phase 4	BBB
PREDNISONE TABLETS Beth Israel Deaconess Medical Center	Phase 4	BBB
DOXORUBICIN Beth Israel Deaconess Medical Center	Phase 4	BBB

View all 50 →

Same molecule, other indications

Lisaftoclax is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaActive

BBB

Indicative · Phase 3

73 / 100

acute myeloid leukemiaActive

B

Indicative · Phase 3

63 / 100

acute promyelocytic leukemiaActive

B

Indicative · Phase 2/3

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.